000			01702 a2200481 4500
005			20250514010610.0
264		0	_c20011207
008			200112s 0 0 eng d
022			_a0269-9370
024	7		_a10.1097/00002030-200109070-00011 _2doi
040			_aNLM _beng _cNLM
100	1		_aLucas, G M
245	0	0	_aComparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz. _h[electronic resource]
260			_bAIDS (London, England) _cSep 2001
300			_a1679-86 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aAdult
650	0	4	_aAlkynes
650	0	4	_aAnti-HIV Agents _xtherapeutic use
650	0	4	_aAntiretroviral Therapy, Highly Active
650	0	4	_aBenzoxazines
650	0	4	_aCD4 Lymphocyte Count
650	0	4	_aCohort Studies
650	0	4	_aCyclopropanes
650	0	4	_aFemale
650	0	4	_aHIV Infections _xdrug therapy
650	0	4	_aHIV Protease Inhibitors _xtherapeutic use
650	0	4	_aHIV-1 _xdrug effects
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aOxazines _xtherapeutic use
650	0	4	_aRNA, Viral _xblood
650	0	4	_aRetrospective Studies
650	0	4	_aReverse Transcriptase Inhibitors _xtherapeutic use
650	0	4	_aRitonavir _xtherapeutic use
650	0	4	_aSaquinavir _xtherapeutic use
650	0	4	_aUrban Population
700	1		_aChaisson, R E
700	1		_aMoore, R D
773	0		_tAIDS (London, England) _gvol. 15 _gno. 13 _gp. 1679-86
856	4	0	_uhttps://doi.org/10.1097/00002030-200109070-00011 _zAvailable from publisher's website
999			_c11469649 _d11469649